Literature DB >> 28658851

Risk Factors and Incidence of Puerperal Genital Haematomas.

Shikha Rani1, Meesha Verma2, Dilpreet Kaur Pandher3, Navneet Takkar4, Anju Huria5.   

Abstract

INTRODUCTION: Puerperal genital haematomas although an uncommon entity but is elusive. This painful condition is not only distressing and dangerous to patient but is embarrassing to the obstetrician who has conducted the delivery. AIM: This study has been planned to evaluate the incidence and risk factors for puerperal genital haematomas.
MATERIALS AND METHODS: A case control study was done from August 2005 to August 2015, of all puerperal genital haematomas. All patients, who had undergone drainage for the puerperal genital haematoma, were enrolled as cases. Two controls were chosen for each case, who had delivered immediately after the case. All the patients were evaluated for the characteristics of haematoma and the management of the same. Cases and controls were compared for the evaluation of risk factors for puerperal genital haematoma.
RESULTS: During the study period 27,826 vaginal deliveries were performed in our institute. Thirty nine haematomas were drained during this period. Incidence of haematomas was one in 1,113 deliveries, in our institute. Among the puerperal haematomas, vulvovaginal was the most common type. Perineal pain was the most common complaint. To evaluate the risk factors, 77 controls were enrolled. Primigravida, hypertensive disease of pregnancy and coagulopathy were the significant risk factors with p-value of <0.01, 0.01 and 0.03 respectively. Episiotomy too was a risk factor with a p-value of 0.002.
CONCLUSION: Primigravida, hypertensive disease of pregnancy, coagulopathy and episiotomy are still the most common risk factors.

Entities:  

Keywords:  Perineal haematomas; Traumatic haematomas; Traumatic postpartum haemorrhage; Vulvovaginal haematomas

Year:  2017        PMID: 28658851      PMCID: PMC5483753          DOI: 10.7860/JCDR/2017/24060.9777

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

1.  Puerperal hematomas. Analysis of 112 cases with a review of the literature.

Authors:  P PEDOWITZ; S POZNER; N H ADLER
Journal:  Am J Obstet Gynecol       Date:  1961-02       Impact factor: 8.661

2.  Perigenital hematomas; analysis of forty-seven consecutive cases.

Authors:  L S SOTTO; R J COLLINS
Journal:  Obstet Gynecol       Date:  1958-09       Impact factor: 7.661

Review 3.  Postpartum hemorrhage: placenta accreta, uterine inversion, and puerperal hematomas.

Authors:  C M Zahn; E R Yeomans
Journal:  Clin Obstet Gynecol       Date:  1990-09       Impact factor: 2.190

4.  Puerperal hematomas; report of 73 cases and review of the literature.

Authors:  T W McELIN; V M BOWERS; R J PAALMAN
Journal:  Am J Obstet Gynecol       Date:  1954-02       Impact factor: 8.661

5.  Evaluation of risk factors in women with puerperal genital hematomas.

Authors:  Cantekin İskender; Hasan Onur Topçu; Hakan Timur; Aslı Oskovi; Gonca Göksu; Ayhan Sucak; Nuri Danışman
Journal:  J Matern Fetal Neonatal Med       Date:  2015-06-05

6.  Practice Bulletin No. 165: Prevention and Management of Obstetric Lacerations at Vaginal Delivery.

Authors: 
Journal:  Obstet Gynecol       Date:  2016-07       Impact factor: 7.661

7.  Perinatal genital hematomas.

Authors:  G N Sheikh
Journal:  Obstet Gynecol       Date:  1971-10       Impact factor: 7.661

8.  Tisseel for management of traumatic postpartum haemorrhage.

Authors:  Jaya Saxena Dhulkotia; M Alazzam; A Galimberti
Journal:  Arch Gynecol Obstet       Date:  2008-11-05       Impact factor: 2.344

9.  Selective arterial embolization as a first-line treatment for postpartum hematomas.

Authors:  Mariagrazia Distefano; Lucia Casarella; Sonia Amoroso; Carmine Di Stasi; Giovanni Scambia; Giovanna Tropeano
Journal:  Obstet Gynecol       Date:  2013-02       Impact factor: 7.661

Review 10.  Puerperal emergency. Vaginal and vulvar hematomas.

Authors:  L E Ridgway
Journal:  Obstet Gynecol Clin North Am       Date:  1995-06       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.